Founder Profile
Steven H. Collis
Last reviewed: 2026 · By Swet Parvadiya
Background
Steven H. Collis joined Chemsource in 1996 and orchestrated the series of aggressive acquisitions that transformed the company into Amerisource Health, later merging with Bergen Brunswig to form AmerisourceBergen. His defining moment was the operational overhaul of the combined entity in the early 2000s, where he slashed costs, unified the IT systems, and pivoted the company toward specialty distribution, saving the company from bankruptcy and establishing the template for its modern dominance.
Founding Story
Steven H. Collis is an American business executive who served as the CEO of AmerisourceBergen (now Cencora) from 2001 until his retirement in early 2024. He played a pivotal role in the company's survival during the early 2000s integration crisis, navigating the massive debt load and operational inefficiencies of the Bergen Brunswig merger to transform the company into the second-largest pharmaceutical distributor in the world. Collis's background in operations and supply chain management gave him a unique perspective on the pharmaceutical industry, driving his focus on operational excellence, specialty pharmacy integration, and global logistics expansion. During his tenure, he oversaw the acquisition of over 50 companies, including World Courier, Healthcare Solutions, and Alto Pharmacy, which generated tens of billions of dollars in cumulative revenue and transformed the company from a traditional wholesale distributor into a diversified healthcare services platform. Collis was also known for his aggressive capital allocation strategy, which prioritized share repurchases and dividend growth while simultaneously managing the massive financial burden of the opioid litigation settlement. Despite the controversy surrounding the opioid crisis, Collis is widely credited with transforming Cencora from a struggling, low-margin distributor into a global healthcare services powerhouse, although his legacy is permanently intertwined with the regulatory and reputational challenges of the pharmaceutical supply chain.